Sign In
Buy ANNX
$5.39
+0.130 (+2.47%)
At Close: Jun 03, 2026
Wall Street Analysts Think Annexon (ANNX) Could Surge 133.72%: Read This Before Placing a Bet
10:55am, Wednesday, 05'th Jun 2024
The consensus price target hints at a 133.7% upside potential for Annexon (ANNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Annexon Announces Proposed Public Offering of Common Stock
05:06pm, Tuesday, 04'th Jun 2024
BRISBANE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devasta
Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place
02:07pm, Tuesday, 04'th Jun 2024
Annexon, Inc. primary endpoint met with statistical significance in phase 3 Bangladesh and Philippines study, using ANX005 for the treatment of patients with Guillain-Barré syndrome. Results from RWS
Annexon's neurological disorder drug meets main goal of late-stage study
07:11am, Tuesday, 04'th Jun 2024
Annexon Inc said on Tuesday its experimental drug to treat a rare neurological disorder met the main goal of a late-stage trial.
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
04:30pm, Monday, 03'rd Jun 2024
BRISBANE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 16'th May 2024
BRISBANE, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
08:00am, Monday, 13'th May 2024
Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024 Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024; Potential to be the Fi
Annexon Biosciences to Present at the Bank of America Health Care Conference
08:00am, Thursday, 09'th May 2024
BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastat
ANX007 demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings
Additional data from the Phase 2 ARCHER trial demonstrating protection of visual acuity and anatomical structure following ANX007 treatment will be featured as an oral presentation
Down -43.02% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon (ANNX)
10:36am, Thursday, 25'th Apr 2024
Annexon (ANNX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates c
Are Medical Stocks Lagging Annexon (ANNX) This Year?
10:46am, Wednesday, 17'th Apr 2024
Here is how Annexon, Inc. (ANNX) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 16'th Apr 2024
BRISBANE, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living wit
Annexon, Inc. (ANNX) Falls More Steeply Than Broader Market: What Investors Need to Know
07:21pm, Wednesday, 10'th Apr 2024
In the latest trading session, Annexon, Inc. (ANNX) closed at $6.17, marking a -0.96% move from the previous day.
Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
08:00am, Wednesday, 03'rd Apr 2024
BRISBANE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devast
